Ozempic - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Cancer patients and survivors who drink alcohol make their treatment less effective and raise their chances of the disease returning — an exigency often ignored by caretakers.

Medications for obesity show promise in curbing alcohol cravings

Bharti Jayshankar January 26, 2024: A recent study has uncovered an unexpected benefit of medications commonly prescribed for obesity and type 2 diabetes:.

by HealthQuill
January 27, 2024
0 Comments

Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people with type 2 diabetes and chronic kidney disease after the interim results met certain pre-specified” criteria for efficacy.

Drugs Health Pharma

Novo Nordisk stops testing of Ozempic as kidney trial meets efficacy goals

HQ Team October 11, 2023: Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people.